Drugs Affecting the Autonomic Nervous System Flashcards

(47 cards)

1
Q

Drugs affecting the autonomic nervous system

A
Alpha2 Agonists
Alpha1 Antagonists
Beta Adrenergic Antagonists
Combined Alpha and Beta Adrenergic Antagonists
Muscarinic Agonists
Cholinesterase Inhibitors
Cholinergic Blockers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Alpha2 Agonists

A

Clonidine
Guanabenz
Guanfacine
Methyldopa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Alpha1 Antagonists

A
Alfuzosin
Doxazosin
Prazosin
Silodosin
Tamsulosin
Terazosin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Beta Adrenergic Antagonists

A
Acebutolol
Atenolol
Metoprolol
Nadolol
Nebivolol
Pindolol
Propranolol
Timolol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Combined Alpha and Beta Adrenergic Antagonists

A

Carvedilol
Labetalol
Epinephrine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Muscarinic Agonists

A

bethanechol (Urecholine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cholinesterase Inhibitors

A
Donepezil
Galantamine
Memantine
Neostigmine
Pyridostigmine
Rivastigmine
Tacrine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cholinergic Blockers

A
Atropine
Benztropine
Darifenacin
Fesoterodine
Dicyclomine
Oxybutynin
Propantheline
Scopalamine
Solifenacin
Mirabegron
Tolterodine (Detrol)
Trihexyphenidyl
Trospium (Sanctura)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Clonidine Pharmacokinetics

A

Onset: Oral 30-60 minutes
Transdermal 2-3 days
Peak: Oral 3-5 hours
Duration: Oral 8 hours
Transdermal: 7 days (8 hours of effect after
patch is removed)
Half-Life: 12-16 hours. Up to 41 hours in impaired renal
function
Elimination: 40-60% unchanged in urine; 50%
metabolized in liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Gunabenz Pharmacokinetics

A
Onset: 60 minutes
Peak: 2-5 hours
Duration: 12 hours
Half-LIfe: 6 hours, prolonged in renal impairment
Elimination: <1% unchanged in urine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Guanfacine Pharmacokinetics

A

Onset: 1 hour
Peak: 1-4 hours
Duration: 24 hours
Half-Life: Adults - 17 hours, Younger Adults- 13 to 14 hr
Elimination: 50% unchanged in urine, 70% in urine
unchanged or as metabolites

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Methyldopa Pharmacokinetics

A

Onset: 2-3 hours
Peak: 2-6 hours
Duration: 12-24 hours
Half-Life: 1.8 hour. Blood pressure reduction is
pronounced and prolonged in renal failure
Elimination: Extensively metabolized in liver; 70% in urine
as metabolites

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Clonidine Interactions

A

-Alcohol, antihistamines, phenothiazines, barbiturates, benzodiazepines
Effect: additive sedation
Implications: Avoid concurrent use
-Beta Adrenergic Blockers
Effect: Attenuation or reversal of antihypertensive
effect of clonidine; may result in life-threatening
hypertension
Implications: Avoid concurrent use; if patient is
taking both drugs and withdrawal is required,
withdraw beta-adrenergic blocker first to prevent
excessive unopposed alpha stimulation that may
lead to malignant HTN.
-Nitrates, other antihypertensives
Effect: additive hypotensive effects
Implications: Avoid concurrent use
-Prazosin
Effect: Decreased antihypertensive effect of
clonidine
Implications: Choose alternative drug
-TCA’s
Effect: Block antihypertensive effects of clonidine
and may result in life-threatening HTN
Implications: Choose alternative antidepressant
-Verapamil
Effect: Synergistic pharmacological and toxic effects
may result in AV block and severe hypotension
Implications: Choose alternative calcium channel
blocker or antihypertensive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Guanabenz/Guanfacine Interactions

A

-Alcohol, antihistamines, phenothiazines, barbiturates, benzodiazepines
Effect: Additive sedative effects
Implications: Avoid concurrent use or choose
alternative antihypertensive
-Alcohol, nitrates, other antihypertensives
Effect: Additive hypotension
Implications: Avoid concurrent use or monitor
BP closely

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Methyldopa Interactions

A

-Alcohol, antihistamines
Effect: Additive sedation
Implications: Avoid concurrent use
-Beta-adrenergic Blockers
Effect: May result in life-threatening HTN
Implications: Less likely with beta1 selective agents
same implications as clonidine
-Haloperidol
Effect: Potentiate antipsychotic effects or may
produce psychosis
Implications: Choose different antipsychotic
-Levodopa
Effect: Potentiate antihypertensive effects of
methyldopa and central effects of levodopa in
Parkinson’s disease
Implications: Avoid concurrent use; choose
alternative antihypertensive
-Lithium
Effect: Increased risk for lithium toxicity
Implications: Choose alternative antihypertensive
-Monoamine oxidase inhibitors (MAOIs)
Effect: Metabolites of methyldopa stimulate release
of endogenous catecholamines that are usually
metabolized by MAOIs; result is excessive SNS
stimulation
Implications: Avoid concurrent use
-Nitrates, other antihypertensives
Effect: Additive hypotension
Implications: Avoid concurrent use
-Phenothiazines, sympathomimetics, barbiturates,
amphetamines
Effect: May result in serious HTN
Implications: Avoid concurrent use
-Tolbutamide
Effect: Tolbutamide metabolism may be impaired,
resulting in enhanced hypoglycemic effects
Implications: Choose alternative hypoglycemic
-TCA’s
Effect: Attenuation or reversal of antihypertensive
effect of methyldopa
Implications: Avoid concurrent use; choose
alternative drugs for depression or HTN
-Herbals: licorice; yohimbe, ginseng
Effect: May affect electrolyte levels. May decrease
efficacy of methyldopa
Implications: Monitor blood pressure and inform
patient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Clonidine Dosing

A

For Hypertension:

ORAL ADULTS
Initial Dose: 0.1 mg bid PO (older adults may need lower dose)

Increase in increments of 0.1 mg PO in weekly intervals

Maintenance Dose: 0.1-0.3 mg bid PO

Max Dose: 1.2 mg BID

TRANSDERMAL
Initial Dose: Catapres 0.1 mg

After 1-2 weeks, if desired BP is not achieved, increase in increments of 0.1 mg/week

Comes in 0.2 mg and 0.3 mg patches

ORAL CHILDREN
12 years and older

Initial Dose: 0.1 mg bid

Increase in 0.1 mg increments at weekly intervals

Maintenance Dose: 0.1-0.3 mg bid

Max Dose: 2.4 mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Clorpress Dosing

Clonidine HCl and Clorthalidone

A

For Hypertension:

Initial Dose: 0.1 mg clonidine plus 15 mg chlorthalidone once or twice daily

Max Dose: 0.6 mg clonidine plus 30 mg chlorthalidone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Guanabenz Dosing

A

For Hypertension:

Initial Dose: 4 mg bid

Increase in increments of 4-8 mg/day every 1-2 weeks until target BP achieved.

Max Dose: 32 mg bid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Guanfacine Dosing

A

For Hypertension:

Initial Dose: 1 mg daily at bedtime

May increase to 2 mg qd after 3-4 weeks if target BP not achieved; 2 mg dose may be given as 1 mg bid

Max Dose: 3 mg qd

20
Q

Methyldopa Dosing

A

For Hypertension:

ADULTS
Initial Dose: 250 mg bid or bid for first 48 ours

Increase in increments of 250 mg every 2 days until target BP is achieved: to minimize sedation, increase dose in evening. Smaller doses should be used in renal impairment

Maintenance Dose: 500-2,000 mg/day in 2-4 divided doses

CHILDREN
Initial Dose: 10 mg/kg/day in 2-4 divided doses

Max Dose: 65 mg/kg or 3,000 mg, whichever is less

21
Q

Alfuzosin Pharmacokinetics

A
Onset: Unknown
Peak: 8 hours
Duration: Unknown
Half-Life: 10 hours
Elimination: 69% in feces; 24% in urine
22
Q

Doxazosin Pharmacokinetics

A
Onset: 60-120 minutes
Peak: 2-3 hours
Duration: 24 hours
Half-Life: 22 hours
Elimination: 63% in bile/feces; 9% in urine
23
Q

Prazosin Pharmacokinetics

A
Onset: 120-130 minutes
Peak: 1-3 hours
Duration: 6-12 hours
Half-Life: 2-3 hours
Elimination: 90% in bile/feces; 10% in urine
24
Q

Silodosin Pharmacokinetics

A
Onset: unknown
Peak: 2.6 hours
Duration: Unknown
Half-Life: 13.8 hours
Elimination: 35.5% in urine; 55% in feces
25
Tamsulosin Pharmacokinetics
``` Onset: Unknown Peak: 5 days Duration: Unknown Half-Life: 9-15 hours Elimination: <10% unchanged in urine ```
26
Terazosin Pharmacokinetics
``` Onset: 15 minutes Peak: 1-2 hours Duration: 12-24 hours Half-Life: 9-12 hours Elimination: 60% in bile/feces; 40% in urine ```
27
Doxazosin Dosing
For Hypertension: Initial Dose: 1 mg daily at bedtime Maintenance Dose: 2-16 mg daily. Depending on standing BP, increase dose in 2 mg increments until target BP is achieved. Doses >4 mg increase risk of postural hypotension. For BPH: Initial Dose: 1 mg daily at bedtime. Extended release form is 4 mg taken once daily at breakfast. Maintenance Dose: 1-8 mg daily. Depending on the urodynamics and BPH symptoms, the dose is increased to 2 mg and then to 4 mg and 8 mg/daily. The recommended maximum dose is 8 mg. The titration interval is 1-2 weeks.
28
Prazosin Dosing
For Hypertension: Initial Dose: 1-2 mg bid or bid; take first dose at bedtime. Maintenance Dose: 6-15 mg/daily in 2-3 divided doses. Depending on standing BP, increase dose in 1 mg increments with the larger dose being given at bedtime until target BP is achieved. Doses >20 mg/day usually do not increase efficacy.
29
Silodosin Dosing
For BPH: Initial Dose: 8 mg once daily with a meal Starting dose may be 4 mg with increases to 8 mg as tolerated.
30
Tamsulosin Dosing
For BPH: Initial Dose: 0.1 mg daily 30 minutes prior to the same meal May be increased after 2-4 weeks to 0.8 mg daily
31
Terazosin Dosing
For Hypertension: Initial Dose: 1 mg daily at bedtime Maintenance Dose: 1-5 mg daily. Depending on standing BP, increase dose in 1 mg increments until target BP is achieved. Doses >20 mg/daily do not increase efficacy. For BPH: Initial Dose: 1 mg daily at bedtime Increased in a stepwise fashion to 2, 5, and then 10 mg. Doses at 10 mg are usually required for clinical effect. Dose may be 10-20 mg daily. Four to 6 weeks are required to assess for beneficial response, so this is the interval for dosage adjustment.
32
Alfuzosin Dosing
For BPH: Initial Dose: 10 mg daily after the same meal Maintenance Dose: 10 mg daily after the same meal
33
Alfuzosin Interactions
-Ketoanazole, itraconazole, ritoniver Effect: decrease metabolism and increase effects of alfuzosin Implication: Avoid concurrent use -cimetidine, atenolol, diltiazem Effect: increase level of alfuzosin and may increase effects of atenolol and diltiazem Implication: Monitor BP and HR -Antihypertensives, calcium channel blockers, nitrates, and alcohol Effect: Increased hypotension risk Implication: Monitor BP or avoid concurrent use
34
Prazosin Interactions
-Beta-adrenergic blockers Effect: May enhance acute postural hypotension following first dose of alpha1 adrenergic blocker Implication: Select different alpha1 adrenergic blocker. No adverse reaction seen with doxazosin or terazosin. -Clonidine Effect: May decrease antihypertensive effect of clonidine. Implication: Avoid concurrent use -Indomethacin Effect: Antihypertensive action of prazosin may be decreased. Implication: Select different alpha1 adrenergic blocker or different NSAID. No adverse reaction with doxazosin or other NSAIDs.
35
Silodosin Interactions
-Calcium channel blockers and thiazides Effect: Increased incidence of dizziness and orthostatic hypotension Implication: Exercise caution and monitor for adverse effects -Azole antifungals, clarithromycin, and other strong CYP3A4 inhibitors Effect: Ketoconazole increased Cmax and AUC Implication: Concomitant use with strong CYP3A4 inhibitors contraindicated -Diltiazem, erythromycin, verapamil, and other moderate CYP3A4 inhibitors Effect: May increase plasma levels Implication: Exercise caution and monitor for adverse effects -Phosphodiesterase type 5 inhibitors (e.g., sildenafil, tadalafil Effect: Increased incidence of orthostatic hypotension Implication: Exercise caution and monitor for adverse effects
36
Tamsulosin Interactions
-Cimetidine Effect: May increase blood levels of tamsulosin, with increased risk for hypotension and toxicity Implication: Select different histamine2 blocker if one must be used
37
Terazosin Interactions
-NSAIDs, sympathomimetics, estrogens Effect: May decrease antihypertensive effects of terazosin Implication: Avoid concurrent use or select doxazosin or another drug class for antihypertensive therapy -Verapamil Effect: Increases serum terazosin levels and may increase sensitivity to terazosin-vnduced postural hypotension Implication: Avoid concurrent use -Finasteride Effect: Increase in peak plasma concentration and AUC of finasteride Implication: Clinical significance unknown; monitor for adverse effects of finasteride
38
Doxazosin, prazosin, tamsulosin, terazosin, alfuzosin Interactions
-Alcohol, antihypertensives, nitrates Effect: Additive hypotension Implication: Avoid concurrent use or administer first dose in the office and monitor BP closely
39
Acebutolol Pharmacokinetics
``` Onset: 60 minutes Peak: 4-6 hours Duration: 24-30 hours Half-Life: 3-4 hours Elimination: 30 to 40% in urine, 50 to 60% in feces/bile ```
40
Atenolol Pharmacokinetics
``` Onset: 60 minutes Peak: 2-4 hours Duration: 24 hours Half-Life: 6-9 hours Elimination: 50% unchanged in urine, rest in feces ```
41
Metoprolol Pharmacokinetics
``` Onset: 15 minutes Peak: 90 minutes Duration: 13-19 hours Half-Life: 3-7 hours Elimination: <5% unchanged in urine ```
42
Nadolol Pharmacokinetics
``` Onset: 5 days Peak: 3-4 hours Duration: 17-24 hours Half-Life: 20-40 hours Elimination: Unchanged in urine ```
43
Nebivolol Pharmacokinetics
Onset: 15 minutes Peak: 1.5-4 hours Duration: Unknown Half-Life: 12-19 hours based on genetic differences Elimination: 38 to 67% in urine, 13 to 44% in feces
44
Pindolol Pharmacokinetics
``` Onset: 7 days Peak: 1 hour Duration: 24 hours Half-Life: 3 to 4 hours Elimination: 60 to 65% metabolites and 35 to 40% unchanged drug in urine ```
45
Propranolol Pharmacokinetics
``` Onset: 30 minutes Peak: 60 to 90 minutes Duration: 6-12 hours Half-Life: 3-5 hours Elimination: <1% unchanged in urine ```
46
Timolol Pharmacokinetics
``` Onset: Unknown Peak: 1-3 hours Duration: 12-24 hours Half-Life: 4 hours Elimination: Metabolites and unchanged drug in urine ```
47
Beta Blockers Interactions
-Aluminum salts, barbiturates, calcium salts, cholestyramine, colestipol, NSAIDs, ampicillin, rifampin, salicylates Effect: Decrease bioavailability and plasma levels of beta adrenergic antagonists, possibly resulting in decreased pharmacological effect Implication: Avoid concurrent use. Separate administration of cholestyramine or colestipol from administration of beta blocker by 4 hour. -Calcium Channel blockers Effect: Potentiate effects of beta blockers Implication: Do not administer within 24 hours of each other. If must give both, monitor for heart failure and decreased peripheral perfusion. -Ciprofloxacin and other quinolone, cimetidine Effect: Bioavailability of beta blocker metabolized by CYP450 may be increased. Implication: Select different antibiotic or different beta blocker